The global fractional flow reserve market was valued at $901.3 million in 2023, and is projected to reach $2.55 billion by 2035, growing at a CAGR of 9.1% from 2024 to 2035.Fractional Flow Reserve (FFR) is a diagnostic measurement used to assess the severity of coronary artery stenosis (narrowing) by evaluating its impact on blood flow. FFR is defined as the ratio of the pressure measured in the coronary artery just beyond the blockage (distal pressure, Pd) to the pressure measured before the blockage, typically in the aorta or a healthy portion of the artery (proximal pressure, Pa). The formula for FFR is Pd/Pa.
There are both invasive and non-invasive methods to assess FFR. Invasive FFR typically involves wired coronary angiography, where a pressure-sensor-equipped guide wire is inserted into the coronary artery during cardiac catheterization. This wire measures pressures before and after the stenosis during induced hyperemia (often using adenosine). These pressure readings are used to calculate the FFR. Intracoronary Ultrasound (IVUS-FFR), which combines imaging with pressure measurements to provide a comprehensive assessment of the artery and stenosis characteristics.
Non-invasive methods include angiography-FFR and computed tomography (CT)-based FFR. X-ray Angiography-FFR uses imaging to visualize blood vessels and assess blood flow dynamics. CT-based FFR employs advanced imaging techniques to simulate blood flow and pressure in coronary arteries, providing insight into stenosis significance without catheterization.
FFR provides an accurate assessment of how much narrowing of coronary arteries is affecting blood flow, helping physicians determine whether the stenosis is likely to cause ischemia (reduced blood flow leading to heart muscle damage). The procedure requires the induction of hyperemia, a state of maximum blood flow and minimal vascular resistance, achieved by administering adenosine.
In a healthy artery, FFR equals 1, indicating no significant obstruction. An FFR value of 0.8 or lower suggests a severe blockage, with high accuracy in predicting ischemia. FFR helps guide treatment decisions, including whether a stent or bypass surgery is needed by providing detailed information about the physiological impact of a coronary stenosis.
Increase in prevalence of cardiovascular diseases, particularly coronary artery diseases (CAD), is a major driver of FFR market growth. As more patients suffer from conditions such as coronary stenosis, healthcare providers seek advanced diagnostic tools including FFR to guide treatment decisions, specifically to determine whether angiography is necessary.
For instance, as per the report of British Heart Foundation, in 2023, it was estimated that globally around 110 million men and 80 million women have coronary heart disease. These conditions result in the narrowing or blocking of coronary arteries, leading to reduced blood flow to the heart muscle and, in severe cases, heart attacks, which lead to surge in demand for fractional flow reserve procedure.
In addition, rise in technological advancements, such as AI-based FFR derived from CT, make the procedure faster and more accessible, encouraging its adoption, thereby fostering market growth. For instance, Cleerly, Inc., a Denver-based healthcare technology company provides Cleerly ISCHEMIA software device that delivers AI-powered coronary artery disease (CAD) risk assessments based on medical imaging results. Further, favorable reimbursement policies and the availability of updated clinical guidelines support FFR integration into routine cardiovascular care, boosting market growth.
However, high cost of FFR devices remains a significant barrier, particularly for smaller healthcare facilities or regions with limited healthcare budgets, thereby restricting market growth. In addition, the need for specialized equipment and trained personnel to perform and interpret FFR measurements limit adoption, especially in underdeveloped markets.
On the other hand, advancements in non-invasive FFR technologies, which make diagnostic procedures less invasive and more accessible, provide an opportunity for market growth especially in the developed and emerging economies. In addition, the rise in healthcare infrastructure in emerging markets offers significant growth potential as these regions increasingly adopt advanced cardiovascular diagnostic tools.
The fractional flow reserve market is segmented into product, technology, application, end user, and region. On the basis of the product, it is classified into guidewires, monitoring systems, and accessories & software. On the basis of technology, the market is categorized into invasive monitoring and non-invasive monitoring. On the basis of application, the market is bifurcated into multi-vessel CAD and single-vessel CAD.
On the basis of end user, the market is fragmented into hospitals, cardiac centres, and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA).
The major companies profiled in the report include Haemonetics Corporation, Abbott Laboratories, Boston Scientific Corporation, Bracco, Koninklijke Philips N.V., HeartFlow, Inc., CathWorks, Siemens, GE HealthCare, and Esaote Group. The key players operating in the market have adopted product approval, acquisition, and agreement as their key strategies to expand their product portfolio.
For instance, in December 2023, Haemonetics Corporation completed its previously announced acquisition of OpSens Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology. OpSens offers the OptoWire, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR).
There are both invasive and non-invasive methods to assess FFR. Invasive FFR typically involves wired coronary angiography, where a pressure-sensor-equipped guide wire is inserted into the coronary artery during cardiac catheterization. This wire measures pressures before and after the stenosis during induced hyperemia (often using adenosine). These pressure readings are used to calculate the FFR. Intracoronary Ultrasound (IVUS-FFR), which combines imaging with pressure measurements to provide a comprehensive assessment of the artery and stenosis characteristics.
Non-invasive methods include angiography-FFR and computed tomography (CT)-based FFR. X-ray Angiography-FFR uses imaging to visualize blood vessels and assess blood flow dynamics. CT-based FFR employs advanced imaging techniques to simulate blood flow and pressure in coronary arteries, providing insight into stenosis significance without catheterization.
FFR provides an accurate assessment of how much narrowing of coronary arteries is affecting blood flow, helping physicians determine whether the stenosis is likely to cause ischemia (reduced blood flow leading to heart muscle damage). The procedure requires the induction of hyperemia, a state of maximum blood flow and minimal vascular resistance, achieved by administering adenosine.
In a healthy artery, FFR equals 1, indicating no significant obstruction. An FFR value of 0.8 or lower suggests a severe blockage, with high accuracy in predicting ischemia. FFR helps guide treatment decisions, including whether a stent or bypass surgery is needed by providing detailed information about the physiological impact of a coronary stenosis.
Increase in prevalence of cardiovascular diseases, particularly coronary artery diseases (CAD), is a major driver of FFR market growth. As more patients suffer from conditions such as coronary stenosis, healthcare providers seek advanced diagnostic tools including FFR to guide treatment decisions, specifically to determine whether angiography is necessary.
For instance, as per the report of British Heart Foundation, in 2023, it was estimated that globally around 110 million men and 80 million women have coronary heart disease. These conditions result in the narrowing or blocking of coronary arteries, leading to reduced blood flow to the heart muscle and, in severe cases, heart attacks, which lead to surge in demand for fractional flow reserve procedure.
In addition, rise in technological advancements, such as AI-based FFR derived from CT, make the procedure faster and more accessible, encouraging its adoption, thereby fostering market growth. For instance, Cleerly, Inc., a Denver-based healthcare technology company provides Cleerly ISCHEMIA software device that delivers AI-powered coronary artery disease (CAD) risk assessments based on medical imaging results. Further, favorable reimbursement policies and the availability of updated clinical guidelines support FFR integration into routine cardiovascular care, boosting market growth.
However, high cost of FFR devices remains a significant barrier, particularly for smaller healthcare facilities or regions with limited healthcare budgets, thereby restricting market growth. In addition, the need for specialized equipment and trained personnel to perform and interpret FFR measurements limit adoption, especially in underdeveloped markets.
On the other hand, advancements in non-invasive FFR technologies, which make diagnostic procedures less invasive and more accessible, provide an opportunity for market growth especially in the developed and emerging economies. In addition, the rise in healthcare infrastructure in emerging markets offers significant growth potential as these regions increasingly adopt advanced cardiovascular diagnostic tools.
The fractional flow reserve market is segmented into product, technology, application, end user, and region. On the basis of the product, it is classified into guidewires, monitoring systems, and accessories & software. On the basis of technology, the market is categorized into invasive monitoring and non-invasive monitoring. On the basis of application, the market is bifurcated into multi-vessel CAD and single-vessel CAD.
On the basis of end user, the market is fragmented into hospitals, cardiac centres, and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA).
The major companies profiled in the report include Haemonetics Corporation, Abbott Laboratories, Boston Scientific Corporation, Bracco, Koninklijke Philips N.V., HeartFlow, Inc., CathWorks, Siemens, GE HealthCare, and Esaote Group. The key players operating in the market have adopted product approval, acquisition, and agreement as their key strategies to expand their product portfolio.
For instance, in December 2023, Haemonetics Corporation completed its previously announced acquisition of OpSens Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology. OpSens offers the OptoWire, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR).
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the fractional flow reserve market analysis from 2023 to 2035 to identify the prevailing fractional flow reserve market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the fractional flow reserve market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global fractional flow reserve market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update* (with the purchase of an enterprise license)
- 5 additional Company Profiles, pre- or post-purchase, as a free update.
- Free Updated Version (once released) with the purchase of an enterprise user license.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Application
- Single vessel CAD
- Multi vessel CAD
By Product
- Guidewires
- Monitoring Systems
- Accessories and Software
By Technology
- Invasive Monitoring
- Non invasive Monitoring
By End User
- Hospitals
- Cardiac Centres
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- Boston Scientific Corporation
- Bracco
- CathWorks
- Esaote Group
- GE HealthCare
- Haemonetics Corporation
- HeartFlow, Inc.
- Koninklijke Philips N.V.
- Siemens
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: FRACTIONAL FLOW RESERVE MARKET, BY PRODUCT
CHAPTER 5: FRACTIONAL FLOW RESERVE MARKET, BY TECHNOLOGY
CHAPTER 6: FRACTIONAL FLOW RESERVE MARKET, BY APPLICATION
CHAPTER 7: FRACTIONAL FLOW RESERVE MARKET, BY END USER
CHAPTER 8: FRACTIONAL FLOW RESERVE MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Bracco
- CathWorks
- Esaote Group
- GE HealthCare
- Haemonetics Corporation
- HeartFlow, Inc.
- Koninklijke Philips N.V.
- Siemens
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 350 |
| Published | November 2024 |
| Forecast Period | 2023 - 2035 |
| Estimated Market Value ( USD | $ 901.3 million |
| Forecasted Market Value ( USD | $ 2550 million |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
